These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
547 related articles for article (PubMed ID: 33130422)
1. Sarcomas: Immune biomarker expression and checkpoint inhibitor trials. Zhu MMT; Shenasa E; Nielsen TO Cancer Treat Rev; 2020 Dec; 91():102115. PubMed ID: 33130422 [TBL] [Abstract][Full Text] [Related]
2. Immunotherapy for sarcomas. Nakata E; Fujiwara T; Kunisada T; Ito T; Takihira S; Ozaki T Jpn J Clin Oncol; 2021 Apr; 51(4):523-537. PubMed ID: 33611603 [TBL] [Abstract][Full Text] [Related]
3. Immune checkpoint inhibitors in treatment of soft-tissue sarcoma: A systematic review and meta-analysis. Saerens M; Brusselaers N; Rottey S; Decruyenaere A; Creytens D; Lapeire L Eur J Cancer; 2021 Jul; 152():165-182. PubMed ID: 34107450 [TBL] [Abstract][Full Text] [Related]
4. Immunotherapy: A New (and Old) Approach to Treatment of Soft Tissue and Bone Sarcomas. Nathenson MJ; Conley AP; Sausville E Oncologist; 2018 Jan; 23(1):71-83. PubMed ID: 28935774 [TBL] [Abstract][Full Text] [Related]
5. Improving Immunotherapy Efficacy in Soft-Tissue Sarcomas: A Biomarker Driven and Histotype Tailored Review. Roulleaux Dugage M; Nassif EF; Italiano A; Bahleda R Front Immunol; 2021; 12():775761. PubMed ID: 34925348 [TBL] [Abstract][Full Text] [Related]
6. Immunotherapy in Sarcoma: Where Do Things Stand? Moreno Tellez C; Leyfman Y; D'Angelo SP; Wilky BA; Dufresne A Surg Oncol Clin N Am; 2022 Jul; 31(3):381-397. PubMed ID: 35715140 [TBL] [Abstract][Full Text] [Related]
7. Phase II study of neoadjuvant checkpoint blockade in patients with surgically resectable undifferentiated pleomorphic sarcoma and dedifferentiated liposarcoma. Keung EZ; Lazar AJ; Torres KE; Wang WL; Cormier JN; Ashleigh Guadagnolo B; Bishop AJ; Lin H; Hunt KK; Bird J; Lewis VO; Patel SR; Wargo JA; Somaiah N; Roland CL BMC Cancer; 2018 Sep; 18(1):913. PubMed ID: 30249211 [TBL] [Abstract][Full Text] [Related]
8. Targeted and immuno-based therapies in sarcoma: mechanisms and advances in clinical trials. Tang F; Tie Y; Wei YQ; Tu CQ; Wei XW Biochim Biophys Acta Rev Cancer; 2021 Dec; 1876(2):188606. PubMed ID: 34371128 [TBL] [Abstract][Full Text] [Related]
9. Undifferentiated and Dedifferentiated Metastatic Melanomas Masquerading as Soft Tissue Sarcomas: Mutational Signature Analysis and Immunotherapy Response. Kasago IS; Chatila WK; Lezcano CM; Febres-Aldana CA; Schultz N; Vanderbilt C; Dogan S; Bartlett EK; D'Angelo SP; Tap WD; Singer S; Ladanyi M; Shoushtari AN; Busam KJ; Hameed M Mod Pathol; 2023 Aug; 36(8):100165. PubMed ID: 36990277 [TBL] [Abstract][Full Text] [Related]
10. T-cell infiltration and clonality correlate with programmed cell death protein 1 and programmed death-ligand 1 expression in patients with soft tissue sarcomas. Pollack SM; He Q; Yearley JH; Emerson R; Vignali M; Zhang Y; Redman MW; Baker KK; Cooper S; Donahue B; Loggers ET; Cranmer LD; Spraker MB; Seo YD; Pillarisetty VG; Ricciotti RW; Hoch BL; McClanahan TK; Murphy E; Blumenschein WM; Townson SM; Benzeno S; Riddell SR; Jones RL Cancer; 2017 Sep; 123(17):3291-3304. PubMed ID: 28463396 [TBL] [Abstract][Full Text] [Related]
11. Expression of lymphocyte immunoregulatory biomarkers in bone and soft-tissue sarcomas. Dancsok AR; Setsu N; Gao D; Blay JY; Thomas D; Maki RG; Nielsen TO; Demicco EG Mod Pathol; 2019 Dec; 32(12):1772-1785. PubMed ID: 31263176 [TBL] [Abstract][Full Text] [Related]
12. Emerging Targeted and Immune-Based Therapies in Sarcoma. Pollack SM; Ingham M; Spraker MB; Schwartz GK J Clin Oncol; 2018 Jan; 36(2):125-135. PubMed ID: 29220291 [TBL] [Abstract][Full Text] [Related]
13. Immunotherapy and Biomarkers in Sarcoma. Dajsakdipon T; Siripoon T; Ngamphaiboon N; Ativitavas T; Dejthevaporn T Curr Treat Options Oncol; 2022 Mar; 23(3):415-438. PubMed ID: 35262852 [TBL] [Abstract][Full Text] [Related]
14. Characteristics and outcomes of patients with advanced sarcoma enrolled in early phase immunotherapy trials. Groisberg R; Hong DS; Behrang A; Hess K; Janku F; Piha-Paul S; Naing A; Fu S; Benjamin R; Patel S; Somaiah N; Conley A; Meric-Bernstam F; Subbiah V J Immunother Cancer; 2017 Dec; 5(1):100. PubMed ID: 29254498 [TBL] [Abstract][Full Text] [Related]
15. Facts and Hopes in Immunotherapy of Soft-Tissue Sarcomas. MartÃn-Broto J; Moura DS; Van Tine BA Clin Cancer Res; 2020 Nov; 26(22):5801-5808. PubMed ID: 32601077 [TBL] [Abstract][Full Text] [Related]
16. Targeted therapies and checkpoint inhibitors in sarcoma. Vasella M; Gousopoulos E; Guidi M; Storti G; Song SY; Grieb G; Pauli C; Lindenblatt N; Giovanoli P; Kim BS QJM; 2022 Dec; 115(12):793-805. PubMed ID: 33486519 [TBL] [Abstract][Full Text] [Related]
17. Immune checkpoint inhibitors in sarcomas: a systematic review. Anastasiou M; Kyriazoglou A; Kotsantis I; Economopoulou P; Kyrkasiadou M; Giannopoulou A; Kosmidou A; Smerdi D; Moutafi M; Gavrielatou N; Psyrri A Immunooncol Technol; 2023 Dec; 20():100407. PubMed ID: 38192615 [TBL] [Abstract][Full Text] [Related]
18. Immunotherapy of heterogenous sarcomas: questions and strategies. Dufresne A; Meurgey A; Brahmi M Curr Opin Oncol; 2019 Jul; 31(4):304-309. PubMed ID: 31033565 [TBL] [Abstract][Full Text] [Related]
19. The emerging role of immunotherapy for the treatment of sarcoma. Klemen ND; Kelly CM; Bartlett EK J Surg Oncol; 2021 Mar; 123(3):730-738. PubMed ID: 33259653 [TBL] [Abstract][Full Text] [Related]
20. The immune subtypes and landscape of sarcomas. Weng W; Yu L; Li Z; Tan C; Lv J; Lao IW; Hu W; Deng Z; Liu Z; Wang J; Xu M BMC Immunol; 2022 Sep; 23(1):46. PubMed ID: 36153483 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]